Sensorion SAS (ALSEN) AI Stock Analysis

• Market Cap: €120.24M
• Dividend Yield: N/A
• Average Volume (3M): 666.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: 55.02%
• Country: FR
• Employees: 63
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 300,661,220
• 10 Day Avg. Volume: 710,511
• 30 Day Avg. Volume: 666,835
• PEG Ratio: -0.02
• Price to Book (P/B): 1.35
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.50
• Price Target Upside: 284.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: €0.50 ▲(28.21%Upside)

The overall stock score reflects Sensorion SAS's financial challenges including net losses and negative cash flows, which are partially offset by its strong equity position and short-term technical momentum. However, the negative P/E ratio remains a significant concern for valuation.

Positive Factors

Clinical Trial Progress

Sensorion has completed enrollment for its Phase 2a study of SENS-401, indicating progress in their clinical trial efforts.

Financial Stability

Sensorion ended the year with EUR77m in cash after two successful funding rounds, ensuring financial stability.

Product Differentiation

Sensorion is differentiated from competitors in the hearing loss gene-therapy space by targeting a younger patient population, which is ideal for a meaningful impact on speech development via SENS-501 treatment.

Negative Factors

Competitor Pressure

Competitor's encouraging updates and fast enrollment in trials raise the stakes for ALSEN's upcoming readout.

Study Delays

Continued delays in the Audiogene study heighten the stakes for upcoming data releases.

Uncertainties in Study Results

There are lingering uncertainties around SENS-401, with mean hearing loss similar between treated and control groups, creating doubts about its effectiveness.

Sensorion SAS Business Overview & Revenue Model

Company Description

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

How the Company Makes Money

Sensorion SAS primarily generates revenue through research and development collaborations, licensing agreements, and potential milestone payments with pharmaceutical partners. The company seeks to advance its drug candidates through clinical trials, aiming to out-license successful therapies to larger pharmaceutical companies that have the resources to commercialize them. Additionally, Sensorion may receive funding from grants and public or private financing rounds to support its ongoing research and development activities.

Sensorion SAS Financial Statement Overview

Summary

Sensorion SAS shows potential with revenue growth and a solid equity base. However, substantial net losses and negative cash flows present significant challenges. The company needs to focus on cost control and operational efficiency to improve profitability and cash flow stability.

Income Statement

Sensorion SAS has experienced revenue growth, but profitability remains a concern. While total revenue increased from the previous year, the company continues to operate at a significant net loss. The gross profit margin is positive, indicating effective revenue management, but negative EBIT and EBITDA margins reflect high operational costs. The consistent net loss indicates a need for improved cost management and revenue enhancement strategies.

Balance Sheet

The company maintains a strong equity position with a low debt-to-equity ratio, suggesting financial stability. Stockholders' equity has improved significantly, indicating investor confidence and capital raising success. However, the persistent net losses continue to erode equity value. The equity ratio is healthy, reflecting a strong capital structure, but ongoing losses could pose risks if not addressed.

Cash Flow

Sensorion SAS exhibits a challenging cash flow position with negative operating and free cash flows. Despite generating significant financing cash flow, largely from equity raises, the company has been unable to generate positive free cash flow. The free cash flow to net income ratio remains negative, reflecting ongoing operational challenges. A focus on improving operating cash flow is essential for long-term financial health.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
6.65M	5.70M	4.93M	4.26M	2.35M
	Gross Profit
6.65M	3.79M	4.16M	3.75M	1.94M
	EBIT
-28.40M	-22.31M	-28.10M	-19.35M	-11.29M
	EBITDA
-27.58M	-21.33M	-22.44M	-14.61M	-8.85M
	Net Income Common Stockholders
-25.97M	-22.06M	-23.21M	-15.14M	-8.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
76.98M	36.97M	26.20M	50.00M	62.17M
	Total Assets
89.28M	46.50M	38.93M	59.02M	67.87M
	Total Debt
2.20M	2.87M	3.76M	3.99M	3.88M
	Net Debt
-64.57M	-34.10M	-369.80K	-7.99M	-46.28M
	Total Liabilities
17.14M	13.23M	17.06M	15.03M	9.52M
	Stockholders Equity
72.14M	33.27M	21.87M	43.98M	58.35M
Cash Flow		Free Cash Flow
-22.45M	-21.94M	-22.92M	-11.81M	-5.48M
	Operating Cash Flow
-21.33M	-21.07M	-21.41M	-10.77M	-5.31M
	Investing Cash Flow
-11.13M	-381.06K	-1.54M	-1.07M	-164.93K
	Financing Cash Flow
62.26M	32.20M	-820.68K	-326.07K	37.23M

Sensorion SAS Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.39
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSEN, the sentiment is Negative. The current price of 0.39 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.36, and below the 200-day MA of 0.59, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.47 is Neutral, neither overbought nor oversold. The STOCH value of 39.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALSEN.

Sensorion SAS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
ALSEN	50 Neutral	€120.24M	―	-49.28%	―	―	55.02%
IPHYF		$189.59M	―	-160.99%	―	―	―
0QAV		€202.61M	―		―	―	―
0OCQ		€128.26M	―	-220.48%	―	―	―
6OP		€122.52M	3.14	86.78%	―	―	―
MAAT	41 Neutral	€82.05M	―		―	44.34%	-27.37%